Core Viewpoint - The company, Shiyao Group, has received approval from the National Medical Products Administration of China to conduct clinical trials for its self-developed chemical Class 1 new drug SYH2061 injection, a double-stranded small interfering RNA (siRNA) drug [1] Group 1: Product Details - SYH2061 is designed for liver-targeted delivery through the conjugation of N-acetylgalactosamine (GalNAc) and aims to effectively reduce the levels of complement protein C5 [1] - The drug is the first domestically developed ultra-long-acting siRNA drug to enter clinical trials for lowering C5 levels, suitable for treating IgA nephropathy and other complement-mediated diseases [1] Group 2: Clinical Development Value - Preclinical studies indicate that SYH2061 demonstrates superior drug activity and sustained efficacy compared to similar siRNA products, showcasing differentiated advantages such as prolonged drug action, good safety profile, and high patient compliance [1]
石药集团(01093)：SYH2061注射液(双链小干扰RNA药物)在中国获临床试验批准